ASH presents advocacy awards to Sen. Dianne Feinstein and Claude Lenfant, M.D.

December 05, 2003

(San Diego, Calif., December 5, 2003) - The American Society of Hematology (ASH) will honor two leaders and champions of health research with this year's Advocacy Awards.

ASH will present the 2003 Public Service Award to Sen. Dianne Feinstein (D-Calif.), and the first-ever Outstanding Lifetime Service Award to Claude Lenfant, M.D., former Director of the National Institutes of Health (NIH) National Heart, Lung, and Blood Institute (NHLBI).

The Society applauds Sen. Feinstein for her leadership in the Senate on medical research and patient care related issues and is pleased to honor her achievements with the 2003 ASH Award for Public Service. Established in 1997, this Award is presented annually by the Society to an elected U.S. public official who has demonstrated effective leadership on issues of importance to hematology research and practice.

Sen. Feinstein has represented California in the Senate since 1992, and serves as the co-chair of the Senate Cancer Coalition as well as vice-chair of the National Dialogue on Cancer. In her 10 years of service in the Senate, she has dedicated herself to fighting cancer by improving research, creating incentives for effective treatments, and improving the quality of care that patients receive. Earlier this year, Sen. Feinstein reintroduced her legislation, the National Cancer Act of 2003, which provides a comprehensive federal effort related to the prevention, early detection, and treatment of cancer.

Dr. Lenfant is the recipient of ASH's first Outstanding Lifetime Service Award. This new award recognizes an individual who has displayed effective leadership in areas relevant to the mission of the Society throughout a lifetime.

Dr. Lenfant, the recipient of the 1999 ASH Award for Outstanding Service, has served as Director of the National Heart, Lung, and Blood Institute for more than 21 years. During his tenure, the Thalassemia Clinical Network, the Blood and Marrow Transplant Clinical Research Network, and the Transfusion Medicine/Hemostasis Clinical Trials Network were all initiated. In addition, Dr. Lenfant led the development of the new NIH-wide loan forgiveness program, which assists clinical and pediatric researchers.

Dr. Lenfant is a major supporter of training the next generation of clinical researchers in hematology, exemplified by the introductory lecture he gave at ASH's first Clinical Research Training Institute in August 2003. Although he is retiring from the Institute, Dr. Lenfant plans to remain active in medicine and research by focusing his efforts on addressing the growing problem of chronic diseases in the developing world.

Dr. Lenfant will be presented with his award on December 7, 2003, during the Plenary Policy Forum at ASH's 45th Annual Meeting in San Diego. Sen. Feinstein will be formally presented with her award in January in Washington, D.C.

The American Society of Hematology's 45th Annual Meeting, to be held December 6-9, 2003, at the San Diego Convention Center, provides hematologists from around the world a forum for discussing critical issues in hematology. Nearly 20,000 clinicians, scientists, and others attend the four-day meeting, which consists of a superb educational program and cutting-edge scientific sessions. For more information, please visit www.hematology.org/meeting.
-end-
For more information about ASH or to obtain photographs of the award recipients, please contact Aislinn Raedy at (202) 776-0544 or by e-mail at araedy@hematology.org.

The American Society of Hematology is the world's largest professional society concerned with the causes and treatment of blood disorders. Its mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems, by promoting research, clinical care, education, training, and advocacy in hematology.

American Society of Hematology

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.